Resultados de profilaxis con itraconazol 800 mg/día vía oral en adultos con leucemia aguda y neutropenia de alto riesgo: Hospital del Salvador 2006-2008
| Autor: | Carolina Guerra C, Alejandro Andrade M, Javiera Molina E, Barbara Puga L, Marisa Capurro C |
|---|---|
| Jazyk: | Spanish; Castilian |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Acute leukemia Chemotherapy Leukemia Itraconazole business.industry Incidence (epidemiology) medicine.medical_treatment lymphoid Myeloid leukemia General Medicine Aspergillosis medicine.disease Leukemia myeloid Gastroenterology Surgery Internal medicine Mycoses fungoides medicine Absolute neutrophil count Adverse effect business medicine.drug |
| Zdroj: | Revista médica de Chile v.139 n.9 2011 SciELO Chile CONICYT Chile instacron:CONICYT |
| Popis: | Background: Systemic fungal infections and specifically invasive aspergillosis (IA) are associated with a high morbi-mortality rate in patients with hematologic malignancies. Itraconazole kinetic studies show that plasma levels are not satisfactory, even though there is a reduction of the severity in clinical cases. Aim: To evaluate the results of oral prophylaxis with high dose itraconazole, 400 mg bid, among patients with adult acute leukemia. Material and Methods: Prospective analysis of 93 high risk febrile episodes (with an absolute neutrophil count of less than 500 x mm3 for more 10 days), that occurred in 76 patients. Results: Seventy five percent of episodes occurred in patients with acute myeloid leukemia and 25% in patients with acute lymphoblastic leukemia. Fifty two percent occurred during the induction of chemotherapy. Median duration of severe neutropenia was 21 days (range 10-48). Median duration of itraconazole prophylaxis was 17 days (range 6-34). A low frequency of invasive fungal infections was observed (17%). According to diagnostic criteria, 5% of episodes corresponded to persistent fever , 1% and 11% of episodes, to probable or possible IA, respectively. No confirmed or proven IA was observed. Mortality of IA was 18%. No serious adverse events due to itraconazole were observed. Conclusions: The use of high dose itraconazole prophylaxis in adult patients with acute leukemia and severe neutropenia was associated to low incidence and mortality of invasive mycoses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|